{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:14:42Z","timestamp":1762460082248},"reference-count":28,"publisher":"American Psychiatric Association Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[1999,3,1]]},"DOI":"10.1176\/ajp.156.3.412","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:17:33Z","timestamp":1659111453000},"page":"412-418","source":"Crossref","is-referenced-by-count":39,"title":["Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks"],"prefix":"10.1176","volume":"156","author":[{"given":"William T.","family":"Carpenter, Jr.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen D.","family":"Lann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan F.","family":"Breier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann T.","family":"Summerfelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC: Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials. Psychol Med 1994; 24:307\u2013316","DOI":"10.1017\/S003329170002729X"},{"key":"R1563BABBHCGE","doi-asserted-by":"crossref","unstructured":"Buchanan RW, Carpenter WT: Targeted maintenance treatment in schizophrenia: issues and recommendations. CNS Drugs 1996; 4:240\u2013245","DOI":"10.2165\/00023210-199605040-00002"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Dixon LB, Lehman AF, Levine J: Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21:567\u2013577","DOI":"10.1093\/schbul\/21.4.567"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Kane JM: Schizophrenia. N Engl J Med 1996; 334:34\u201341","DOI":"10.1056\/NEJM199601043340109"},{"key":"R1563BABJFACG","doi-asserted-by":"crossref","unstructured":"Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19:287\u2013302","DOI":"10.1093\/schbul\/19.2.287"},{"key":"R1563BABDFGCB","doi-asserted-by":"crossref","unstructured":"Hogarty GE, McEvoy JP, Magnets M, Dauber AL, Barbone P, Casher R, Cooley SJ, Ulrich RF, Carter M, Madonia MJ, Environmental\/Personal Indicators in the Course of Schizophrenia Research Group: Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results of a two-year controlled study. Arch Gen Psychiatry 1988; 45:797\u2013805","DOI":"10.1001\/archpsyc.1988.01800330021002"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramon-Lorenzi J: Low-dose neuroleptic treatment of outpatient schizophrenics, I: preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40:893\u2013896","DOI":"10.1001\/archpsyc.1983.01790070083010"},{"key":"R1563BABIEIBI","doi-asserted-by":"crossref","unstructured":"Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA: Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987; 44:518\u2013521","DOI":"10.1001\/archpsyc.1987.01800180028005"},{"key":"R1563BABDBJJG","doi-asserted-by":"crossref","unstructured":"Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG: Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry 1997; 54:453\u2013463","DOI":"10.1001\/archpsyc.1997.01830170079011"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Carpenter WT, Heinrichs DW: Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 1983; 9:533\u2013542","DOI":"10.1093\/schbul\/9.4.533"},{"key":"atypb6","doi-asserted-by":"crossref","unstructured":"Carpenter WT Jr, Heinrichs DW, Hanlon TE: A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987; 144:1466\u20131470","DOI":"10.1176\/ajp.144.11.1466"},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW: Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147:1138\u20131148","DOI":"10.1176\/ajp.147.9.1138"},{"key":"atypb8","doi-asserted-by":"crossref","unstructured":"Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J: Intermittent vs maintenance medication in schizophrenia. Arch Gen Psychiatry 1991; 48:333\u2013339","DOI":"10.1001\/archpsyc.1991.01810280049007"},{"key":"atypb9","doi-asserted-by":"crossref","unstructured":"Jolley AG, Hirsch SR, McRink A, Manchanda R: Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989; 298:985\u2013990","DOI":"10.1136\/bmj.298.6679.985"},{"key":"R1563BABCDEJJ","doi-asserted-by":"crossref","unstructured":"Pietzcker A, Gaebel W, Kopcke W, Linden M, M\u00ef\u00bf\u00bdller P, M\u00ef\u00bf\u00bdller-Spahn F, Tegeler J: Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia\u20142-year results of a German multicenter study. J Psychiatr Res 1993; 27:321\u2013339","DOI":"10.1016\/0022-3956(93)90059-B"},{"key":"R1563BABEBDBF","doi-asserted-by":"crossref","unstructured":"Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B: Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. J Clin Psychopharmacol 1981; 1:141\u2013145","DOI":"10.1097\/00004714-198105000-00005"},{"key":"R1563BABHBIGI","doi-asserted-by":"crossref","unstructured":"Wistedt B, Jorgensen A, Wiles D: A depot neuroleptic withdrawal study: plasma concentration of fluphenazine and fluphenthixol and relapse frequency. Psychopharmacology (Berl) 1982; 78:301\u2013304","DOI":"10.1007\/BF00433729"},{"key":"R1563BABDIEEB","doi-asserted-by":"crossref","unstructured":"Hawk AB, Carpenter WT, Strauss JS: Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry 1975; 32:343\u2013356","DOI":"10.1001\/archpsyc.1975.01760210077005"},{"key":"R1563BABCGCCA","doi-asserted-by":"crossref","unstructured":"Heinrichs DW, Hanlon TE, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388\u2013398","DOI":"10.1093\/schbul\/10.3.388"},{"key":"R1563BABHCCBF","doi-asserted-by":"crossref","unstructured":"Cassady SL, Thaker GK, Summerfelt A, Tamminga CA: The Maryland Psychiatric Research Center Scale and the characteristics of involuntary movements. Psychiatry Res 1997; 70:21\u201337","DOI":"10.1016\/S0165-1781(97)03031-X"},{"key":"R1563BABBHCDG","doi-asserted-by":"crossref","unstructured":"Lee ET, Desu MM: A computer program for comparing K samples with right-censored data. Comput Programs Biomed 1972; 2:315\u2013321","DOI":"10.1016\/0010-468X(72)90019-0"},{"key":"R1563BABIICFE","doi-asserted-by":"crossref","unstructured":"Blackwelder WC, Chang MA: Sample size graphs for \u201cproving the hypothesis.\u201d Control Clin Trials 1984; 5:97\u2013105","DOI":"10.1016\/0197-2456(84)90116-8"},{"key":"R1563BABGIADA","doi-asserted-by":"crossref","unstructured":"Strauss JS, Carpenter WT: The prediction of outcome in schizophrenia, II: relationships between predictor and outcome variables: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry 1974; 31:37\u201342","DOI":"10.1001\/archpsyc.1974.01760130021003"},{"key":"R1563BABHIBIC","doi-asserted-by":"crossref","unstructured":"Arvanitis LA, Miller BG: Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42:233\u2013246","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"R1563BABEFEFC","doi-asserted-by":"crossref","unstructured":"Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:407\u2013418","DOI":"10.1097\/00004714-199710000-00010"},{"key":"R1563BABFAGID","doi-asserted-by":"crossref","unstructured":"Chouinard G, Jones B, Remington G, Bloom DJ, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25\u201340","DOI":"10.1097\/00004714-199302000-00004"},{"key":"R1563BABJCFBC","doi-asserted-by":"crossref","unstructured":"Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825\u2013835","DOI":"10.1176\/ajp.151.6.825"},{"key":"R1563BABFIAJC","doi-asserted-by":"crossref","unstructured":"M\u00ef\u00bf\u00bdller-Spahn F: Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol (abstract). Clin Neuropharmacol 1992; 15:90A\u201391A","DOI":"10.1097\/00002826-199201001-00048"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ajp.psychiatryonline.org\/doi\/10.1176\/ajp.156.3.412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T15:53:00Z","timestamp":1722181980000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.156.3.412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3,1]]}},"alternative-id":["10.1176\/ajp.156.3.412"],"URL":"https:\/\/doi.org\/10.1176\/ajp.156.3.412","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3,1]]}}}